UMMS Central Biorepository

College of American Pathologists Accredidated

The Central Biorepository (CBR) is a unit of the UMMS Office of Research and part of the Medical School's Strategic Research Initiative. We enhance the research portfolio by providing a world-class, accredited, standardized, safe and monitored environment for the processing, storage and distribution of high-quality normal and disease biospecimens annotated with detailed clinical and laboratory data.

technician loading reagent on extraction robot

The centralized biorepository is an enterprise resource fostering collaboration among UMMS investigators by providing access to biospecimens annotated with research and clinical data.  The CBR is home to hundreds of thousands of biospecimens annotated with clinical data.  Investigators with level-2 passwords can identify specimen cohorts through DataDirect.

A variety of biospecimens, including, serum, plasma, DNA, urine, frozen tissue, etc. are available to researchers with a qualified use proposal.  Samples have been collected under the following research programs:

Analgesic Outcomes Study

PI: Chad Brummett, M.D.

Any patient who is receiving a group of pre-specified group of surgeries are eligible to participate (e.g. total knee and hip arthroplasty, hysterectomy, thoracic surgery). Patients must be 18 years of age or older. Patients are asked to complete 10-15 minutes worth of questionnaires pre-operatively about pre-operative pain and overall health and well-being. Participation also includes brief follow up phone calls and/or mailings for questions of pain, mood and function. Phone call follow-ups are typically less than 10 minutes. The packet that is sent in the mail is very similar to the packets filled out on the day of surgery. Blood samples are sequenced for the genome/genetic material and stored securely at University of Michigan. As of December 2015, AOS participation no longer requires genetic analyses; however, many patients are co-enrolled in MGI to allow for genetic analyses.

(more info)

Cardiovascular Health Improvement Project (CHIP)

PI: Cristen Willer, PhD

Cardiovascular Disease (CVD) is one of the leading causes of death in the United States. The goal of the Cardiovascular Health Improvement Project (CHIP) is to learn more about individuals with aortic diseases and other cardiovascular-related conditions through collecting and analyzing blood and clinical data from patients.  By doing this, we can learn more about the genetics behind  CVD, help clinicians provide the best care for their patients, and lower the incidence of CVD.

When we began biobanking in the Fall of 2013, we focused exclusively on patients with aortic disease diagnoses. Since then we have gone through several expansions in terms of the patient populations we enroll.  As of 2016, we have expanded into heart failure, arrhythmia, and dyslipidemia.  We are currently enrolling patients who have one or more of the following diagnoses or demographics: aortic disease, connective tissue disorders, bicuspid aortic valve, and heart failure.

Clinical Phenotyping Resource and Biobank Core (C-PROBE)

PI: Matthias Kretzler, M.D.

Chronic kidney disease (CKD) affects approximately 26 million Americans and disproportionately manifests in specific race and ethnic groups. Patients burdened with CKD have significant morbidity and reduced life expectancy. In addition to excessive suffering and lost productivity, the cost of managing this epidemic has reached $40 billion annually. The recognition that CKD is a major public health problem is reflected in the fourteen objectives outlined in Healthy People 2020 to begin to address the disease burden.

The Clinical Phenotype Resource and Biobank Core (C-PROBE) is well positioned to drive T1 translational research to promote medical advancement in CKD. C-PROBE is the human subjects core of the Michigan O’Brien Kidney Translational Core and the main cohort is funded by the NIDDK (2P30DK081943-06) and the University of Michigan. The main focus of C-PROBE is to develop and maintain an infrastructure that will serve as an interface between patients in the clinical care setting (in southeast Michigan, Chicago, IL, Philadelphia, PA and Charlotte, NC) and biomedicalinvestigators to streamline translational research in kidney disease.

(more info)

Inflammatory Bowel Disease Databank

PI: Peter Higgins, M.D., Ph.D.

The Inflammatory Bowel Disease (IBD) Databank seeks to collect clinical, immunologic, genetic, and survey data from patients with IBD. Currently, IBD is poorly understood. It appears to be due to an abnormal interaction between the microbiologic flora of the intestine and the immune system of a genetically susceptible individual. The resulting chronic inflammatory response causes structural damage to the intestine, waxing and waning flares of inflammation, and increased risk of colon cancer. The information collected will be used to correlate data on subjects with IBD in an exploratory fashion, to generate hypotheses about epidemiology, pathophysiology, and causation. Because we believe there are subtypes of disease, the data may lead to new directions and studies in the therapy of IBD in one or more of these subtypes.

Investigational Weight Management Clinic

PI: Charles Burant, M.D.

The Weight Management Program at the University of Michigan was created to identify strategies that will result in cost-effective, long term weight management for overweight and obese individuals. The driving hypothesis of the clinic is that the ‘one size fits all’ philosophy is untenable with a complex disease such as obesity. The clinic will serve as a portal for patients to choose st andard clinical care or to explore alternatives from a variety of clinical studies offered through the clinic. These studies will include further investigations into nutrition, the biological basis of weight and weight management and protocols using approved and experimental pharmaceuticals.

(more info)

Michigan Genomics Initiative

PI: Gonçalo Abecasis, Ph.D.

The Michigan Genomics Initiative (MGI) aims to create an institutional repository of DNA and genetic data for broad long-term use. All pre-operative patients 18 years of age or older are eligible for participation in the Medical School Central Biorepository. The biorepository in essence, is a genetic library for researchers at University of Michigan and at other research institutions, including the National Institute of Health, to use for several types of studies. Participation includes a small blood sample on the day of surgery and filling out a short questionnaire regarding pre-operative pain and basic lifestyle questions. Patients may be contacted in the future for any study that is conducted through the biorepository. Blood samples are sequenced for the genome/genetic material and stored securely at the University of Michigan.

(more info)


PI: Charles Burant, M.D.

We propose to discover genetic loci and variants that influence type 2 diabetes mellitus (T2DM) risk and variability in T2DM­related quality traits. Our aim is to identify genetic variants that predispose individuals to T2DM and that are responsible for variability in T2DM­related quantitative traits locally and globally. Our hypothesis is that certain genetic variants increase the risk for T2DM and its complications. Genetic studies have detected >70 loci associated with T2D and >400 for the related quantitative traits (QTs) of glucose and insulin, body mass index (BMI) and waist­to­hip ratio (WHR), lipids, and blood pressure. However, the causal variants and functional units (e.g. genes, promoters, enhancers) remain largely unknown. GWAS data on larger samples, genotype data for arrays like Metabochip and exomechip, analysis of more detailed phenotypes, and analysis across multiple ethnicities, will help fine­map existing T2D and QT loci, identify additional independent variants at know loci, and identify novel loci. More complete lists of T2D and QT loci will increase power for pathway analysis, and provide additional opportunities to identify loci that appear particularly tractable for functional studies or as drug targets.

(more info)

Nephrotic Syndrome Study Network (NEPTUNE)

PI: Matthias Kretzler, M.D.

The Nephrotic Syndrome Study Network (NEPTUNE) is a North American multi-center collaborative consortium established to develop a translational research infrastructure for Nephrotic Syndrome. This includes a longitudinal observational cohort study, a pilot and ancillary studies program, a training program, and a patient contact registry. NEPTUNE will enroll 450 adults and children with minimal change disease, focal segmental glomerulosclerosis and membranous nephropathy for detailed clinical, histopathologic, and molecular phenotyping at the time of clinically-indicated renal biopsy. Initial visits will include an extensive clinical history, physical examination, collection of urine, blood and renal tissue samples, and assessments of quality of life and patient-reported outcomes. Follow-up history, physical measures, urine and blood samples, and questionnaires will be obtained every 4 months in the first year and bi-annually, thereafter. Molecular profiles and gene expression data will be linked to phenotypic, genetic, and digitalized histologic data for comprehensive analyses using systems biology approaches. Analytical strategies were designed to transform descriptive information to mechanistic disease classification for Nephrotic Syndrome and to identify clinical, histological, and genomic disease predictors. Thus, understanding the complexity of the disease pathogenesis will guide further investigation for targeted therapeutic strategies.

(more info)

Prechter Bipolar Genetic Repository

PI: Melvin McInnis, M.D.

As part of the Heinz C. Prechter Bipolar Genes Project, the Prechter Bipolar Genetics Repository has been established to study and conquer bipolar disorder. Our repository is the nation’s largest privately-funded bipolar genetics repository, and is collecting DNA samples from people who have been diagnosed with bipolar disorder as well as healthy individuals. The University of Michigan is collaborating on this effort with our independently approved partner sites: Johns Hopkins, Penn State, Stanford and Weill Cornell Universities.

Together, these investigators are working with their research teams on specific studies to collect phenotypic information, or observable traits, and DNA on thousands of bipolar individuals and control participants. They are also collecting a depth of data and biological materials gathered on the research participants who contribute the samples, including imaging data, electrophysiology, nutrition,stem cells, sleep, medication data, and speech data. The repository data has a richness unlike any other collection of bipolar research data in the world.

The Genetics Repository enables pilot studies to address bolder questions. Studies that are based on new findings will be able to proceed more expeditiously. The Genetics Repository is a vitally important tool to rapidly accelerate genetic research, one of the most significant areas of study today.

The goal of the Prechter Bipolar Genetics Repository is to one day provide confidential, coded DNA samples and clinical information to scientists worldwide to accelerate knowledge breakthroughs.

(more info)